The global blood glucose test strips market size was USD 12.35 Billion in 2021 and is expected to register a revenue CAGR of 6.1% during the forecast period. Increasing global prevalence of type-2 diabetes, rising demand for home blood glucose monitoring systems among an increasing number of patients with diabetes and hypoglycemia, and steady shift from venipuncture blood sugar tests to easy-to-use test kits are some of the key factors expected to drive market revenue growth over the forecast period. Also, rising prevalence of diabetes-related diseases such as Cardiovascular Disease (CVD), neuropathy, and nephropathy and increasing awareness regarding benefits of early detection of diseases and preventive measures are other factors resulting in adoption of blood glucose test strips among the diabetic patient pool. This is also projected to augment revenue growth of the market to a significant extent between 2022 and 2030.
Self-Monitoring Blood Glucose (SMBG) devices, such as test strips, which are used in conjunction with glucometers enable checking of blood glucose irregularities and levels. Monitoring aids in preventing diabetic hypoglycemia and other potential medical conditions early on. Diabetes is characterized by glucose levels in the blood exceeding 200mg/dL two hours after a meal. Diabetes prevalence has been increasing rapidly and is not restricted to a particular age group. According to the International Diabetes Federation (IDF), approximately 537 million adults were diabetic in 2021, which is projected to increase to 643 million by 2030. Treatment and prevention of diabetes burdens patients with direct medical costs. Also, according to the 2016 Global Report on Diabetes by World Health Organization (WHO), losses in global Gross Domestic Product (GDP) from 2011 to 2030 due to direct and indirect costs of diabetes is projected to be USD 1.7 trillion.
Request a Sample@ https://qyresearchmedical.com/sample/119107
Among the two types of SMBG devices on the market currently, consumables, which includes test strips, is more preferred than continuous glucose monitoring systems, and accounts for around 90% of the total revenue, according to a 2021 Health Action International (HAI) report. Test strips are easy and convenient to use, minimally invasive, and does not require surgical procedure for checking blood glucose level.
Driver: Increasing global prevalence of type-2 diabetes is driving the blood glucose test strips market revenue growth
Various factors known to cause diabetes include weight gain and obesity, family history, overconsumption of food, limited physical activity and sedentary lifestyle, and even pregnancy. Long-term diabetes can result in CVDs, neurological problems, and kidney damage, among others. Prevalence of various diseases as a result of diabetes has also been increasing at a significantly steady rate in the recent past. According to the International Diabetic Federation (IDF) Atlas, the global number of diabetic patients have increased from 366 million in 2011 to 536 million in 2021. WHO data indicates that CVDs account for approximately 17.9 million deaths annually. The mortality rate can be reduced by periodic monitoring of blood sugar levels to treat diabetes. Blood glucose test kits, which include a glucometer and analytical test strips, enable patients to conveniently check blood sugar levels. Hypoglycaemia, which occurs when glucose levels are below 70mg/dL and is generally associated with geriatric patients being treated for multiple diseases. Fasting, use of insulin, and alcohol consumption are common causes of Hypoglycaemia, and can be controlled by regular blood glucose monitoring.
Nephropathy, also known as End-Stage Renal Disease (ESRD), which is the deterioration in functioning of kidneys is frequently attributed to diabetes. Globally, over 50,000 deaths were attributed to ESRD during a 6-month period in 2020. The condition can be treated by controlling diabetes and high blood pressure. Rising incidence of kidney failure globally is driving adoption of blood glucose test strips, which is expected to continue to support market revenue growth. Diabetic Ketoacidosis (DKA), which results from metabolism of fat due to deficiency of glucose results in accumulation of ketones in blood, and decreases pH, and unless treated, is a life-threatening disease. SMBG devices, particularly test strips, enable patients of DKA to keep their blood glucose levels in check and avoid potential severity.
requirement for glucose testing on strips is causing reluctance among some patients
Glucometer test kits include a lancet, which is used by a patient for fingerprick in order to draw blood for the test strip. However, this procedure causes some pain, which results in reluctance among some patients to adopt such tests. The strips have short expiry periods, cannot be reused, and are sensitive to changes in temperature, sample quality, and humidity. In addition, glucometer tests are not considered accurate for diabetic patients with hypotension, anemia, and altered hematocrit. Cost of device is one-time investment, but significant high cost of test strips increases burden on patients. This among others, is a major factor expected to hamper market revenue growth to some extent.
The blood glucose test strips market has recovered to a major extent after the severe slump and supply chain disruptions as a result of the COVID-19 pandemic. Medical equipment industries are steadily resuming manufacture of continuous and test strip-based blood glucose monitoring devices to cater to the demand-supply gap. Supply chains have resumed and enabled easier acquisition of raw materials and enzymes required for producing test strips. Unhealthy food habits, lack of physical activity, and unhealthy lifestyle during the pandemic has led to unchecked increase in blood glucose levels among a number of individuals. Implementation of lockdown across countries decreased access of medical centres to diabetic and pre-diabetic patients. This has caused a shift in patient preference towards SMBG devices. In addition, researchers in the Johns Hopkins University have developed a COVID-19 test kit based on the design of test strips-operated glucometers, which is expected to accelerate the number of covid tests, and in turn increase demand for test strips. Furthermore, diabetes has been indicating a potentially high prevalence rate among patients with COVID-19. According to Journal of the American Medical Association (JAMA), patients with COVID-19 were 166% more likely to receive a new diabetes diagnosis than age- and sex-matched patients without COVID-19. In addition, COVID-19 patients are also 116% more likely to be newly diagnosed with diabetes than similar patients who had an acute respiratory infection during pre-pandemic times.
Distribution Type Outlook:
Based on type, global blood glucose test strips market has been segmented into Over-The-Counter (OTC) and online. Over the counter segment is expected to account for a significantly robust revenue share over the forecast period. Product quality assurance and high preference and easy availability of SMBG devices through retail stores and pharmacies are major factors driving revenue growth of this segment. Low and Middle-Income Countries (LMICs), which account for around 97% revenue from sales of SMBG devices are primarily dependent on public and private retail pharmacy channels for purchasing glucometer kits. Also, patients who are unable to use the strips or pen needles on their own visit nearby pharmacies for assistance. This is increasing dependence among a number of diabetic patients on pharmacies, and is in turn boosting revenue growth of this segment.
Online segment is expected to register a rapid revenue CAGR during the forecast period. Ease of placing orders and lower prices are some of the major factors expected to support revenue growth of the online segment. Rapid growth and traction of e-Commerce platforms has made access to medical devices and test kits easy and convenient, especially for elderly individuals and those with mobility issues. Wider range of products available on online platforms and lower cost than that at retail channels is making online purchasing increasingly popular and driving market revenue growth.
Diabetes Type Outlook:
Based on application, the global blood glucose test strips market has been segmented into type-1 diabetes, type-2 diabetes, prediabetes, gestational diabetes, and others. Type-2 diabetes segment is expected to register a significantly robust revenue growth rate over the forecast period. Type-2 diabetes affects a sizable number of individuals worldwide, and the number is substantially high in The U.S. According to the Centers for Disease Control and Prevention (CDC), around 90–95% of the 37 million U.S. diabetic population suffer from type-2 diabetes. Rising cases of type-2 diabetes in countries in the Asia Pacific region is expected to increase demand of blood glucose test strips and boost revenue growth of the market. In addition, countries such as Pakistan, Malaysia, India, and China, among others are expected to remain major consumer hubs for blood glucose test strips in future.
Type-1 diabetes segment is expected to register a steady revenue growth rate over the forecast period. According to Juvenile Diabetes Research Foundation (JDRF), around 1.6 million individuals have been diagnosed with type-1 diabetes in the US. This form of diabetes results from insulin deficiency, thereby requiring insulin to be administered externally on a daily basis. Regulated diets are prescribed for patients with T1D in order to control sugar levels. The American Diabetes Association (ADA) recommends testing blood glucose levels for 6-10 times/day for T1D patients, which is expected to increase adoption of test strips and support revenue growth of this segment.
Based on end-use, the global blood glucose test strips market has been segmented into hospitals, diagnostic centers, nursing homes and polyclinics, and pharmacies and retail outlets. Hospitals segment is expected to account for significantly large revenue share over the forecast period. Usage of glucose meter kits for analysing blood glucose levels accelerates the operational time, as these tests provide rapid results, as opposed to conventional laboratory tests, which could take two to four hours. In addition, SMBG devices are minimally invasive and less painful and a lancet used to draw a drop of blood for testing on the strip. The method is convenient for patients who do not prefer venipuncture methods through syringes or suffer from hemophobia. Preference among some patients to visit hospitals for blood glucose testing by trained medical practitioners is another factor driving revenue growth of this segment.
Pharmacies and retail outlets segment revenue is projected to register a rapid CAGR from 2022 to 2030. Sales of self-monitoring blood glucose devices is high through pharmacies, retail outlets, and also on e-Commerce platforms. This can be attributed to ease of use of such devices and rising preference among an increasing number of patients, especially post-COVID-19 outbreak, for home-based diagnostic tests and monitoring. According to recommendations of the American Diabetes Association (ADA), patients with type-1 diabetes need to check blood glucose levels a number of times each day. Bulk purchase of test strips makes this process more affordable and convenient, and is expected to continue to support revenue growth of this segment.
Asia Pacific blood glucose test strips market is expected to account for largest revenue share in the global market during the forecast period. Rapid rise in prevalence of diabetes in countries in this region is a major factor driving market revenue growth. According to the IDF Atlas, 74.1 million people in India had diabetes in 2021, which is projected to increase to 92.9 million in 2030.
North America blood glucose test strips market is expected to register a steady revenue CAGR over the forecast period due to robust presence of key manufacturers in countries in the region. Prevalence of diabetes and CVDs has been increasing and the number of deaths has also been relatively high. Around 659,000 deaths are recorded each year in the U.S. as a result of CVDs. Rising focus on early detection of various diseases and conditions is also resulting in a number of health-conscious individuals opting for blood glucose tests and level monitoring in countries in the region. Increasing patient preference to adopt self-monitoring blood glucose devices is expected to continue to drive revenue growth of the North America blood glucose test strips market going ahead.
Europe blood glucose test strips market is expected to account for a relatively large revenue share in the global market during the forecast period. Obesity and overweight are some key causes for high prevalence of diabetes in countries in the region, with 60 million individuals having the disease. According to IDF projections, diabetes prevalence is slightly short of 10% and 61 million have diabetes in EUR Region. This is expected to increase by around 13% by 2045. Children and adolescents with type 1 diabetes was 295,000 and the region also had the highest incidence annually at 31,000 new cases per year. Spending on diabetes in 2021 was USD 189.3 billion, which was 19.6% of the total diabetes spending worldwide. Increasing awareness about diabetes and need to take measures to treat the disease are key factor among individuals in countries in the region, and this is expected to drive market revenue growth over the forecast period.
Competitive landscape of the global blood glucose test strips market is moderately fragmented with many key players operating on global and regional levels. Key players are engaged in product and medical device and test kit development and trials, and engaging in strategic alliances and agreements to expand their respective portfolios and gain a robust footing in global market. Some major companies in the global market report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Agamatrix, Ascensia Diabetes Care Holdings AG, LifeScan, Inc., ARKRAY, Inc., Medtronic plc, Bionime Corporation, Care Touch LLC, and DarioHealth Corporation.
- On 04 April 2022, Ascensia Diabetes Care announced the launch of Eversense E3 Continuous Glucose Monitoring (CGM) System, which will be available for use for patients in the U.S. Developed by Senseonics Holdings, Inc., the product has been approved by the Food and Drug Administration (FDA) for a usage period of six months, which is the longest period for any commercially available CGM sensor in the U.S. Ascensia has designed the Eversense Payment Assistance and Simple Savings (PASS) Program, which is expected to make the CGM systems more accessible and affordable to patients of irregular blood glucose levels.
- On 04 April 2022, Abbott Laboratories announced the approval of the Aveir single chamber leadless pacemaker by the U.S. Food and Drug Administration (FDA). The product, which is designed for treatment of patients with slow cardiac rhythms, is implanted in the right ventricle of the patient through a minimally invasive procedure, without a chest incision. The FDA approval is expected to bolster advancements in treatment of cardiac patients.
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country-level, and provides an analysis of market trends in each segment and sub-segments from 2022 to 2030. For the purpose of this report, Reports and Data has segmented the global blood glucose test strips market based on distribution type, diabetes type, end use, and region:
Blood Glucose Test Strips Market Report Scope
Segments covered By Distribution Type Outlook, Diabetes Type Outlook, End-Use Outlook, Regional Outlook
By Distribution Type Outlook
Over the counter
By Diabetes Type Outlook
By End-Use Outlook
Nursing Homes and Polyclinics
Pharmacies and Retail Outlets
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119107/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: